State-of-the-Art Cancer Immunotherapies—2nd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 15 August 2024 | Viewed by 90
Special Issue Editors
Interests: cytokines; antitumor immunity; vaccine; regenerative medicine; mesenchymal stem cells; autoimmune diseases; allergic diseases; inflammatory diseases; sensitization; hapten
Special Issues, Collections and Topics in MDPI journals
Interests: Th; Treg; CTL; CAR-T; TAM; metabolism; tumor immunity; cancer vaccine
Special Issues, Collections and Topics in MDPI journals
Interests: inflammation; inflammatory diseases; cytokines; parasite infection; immune regulation; tumor immunity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The current global success in the protection against COVID-19 through vaccination has proved the effectiveness and safety of the mRNA vaccine delivered by lipid nanoparticles. Such breakthroughs, including cancer vaccination; adoptive cell transfer therapy using CAR-T cells, TCR-T cells, and iPS cell-derived cells; immune checkpoint inhibitors; antibody therapy; dendritic cell therapy; and molecular targeting therapy, have greatly improved cancer patient outcomes. However, the overall survival rate is still unsatisfactory; therefore, it is necessary to much better understand the molecular mechanisms of cancer development and progression in the immunosuppressive tumor microenvironment.
In this Special Issue, we will focus on the latest advances in research on cancer immunotherapy ranging from basic research to clinical aspects that may advance our understanding of human cancer. Since IJMS is a journal of molecular science, pure clinical studies such as case reports will not be suitable for submission, but clinical submissions such as biomolecular experiments are welcome.
Prof. Dr. Takayuki Yoshimoto
Dr. Takuma Kato
Dr. Hisashi Nagase
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint inhibitors
- antibody therapy
- cytokines/chemokines
- CAR-T and TCR-T cells
- iPS cell-derived cells
- dendritic cell therapy
- vaccine
- inflammation
- mesenchymal stem cells
- immunosuppressive tumor microenvironment
